UNSPSC 51192203: Hydrochlorothiazide/spironolactone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV704. This VA Drug Class (CV704) classifies this compound as belonging to the group POTASSIUM SPARING/COMBINATIONS DIURETICS.

UNSPSC 51192203 Hydrochlorothiazide/spironolactone is a Commodity code that in recent state and local practice covers generic pharmaceuticals and over-the-counter products supplied through cooperative purchasing agreements and direct municipal procurement. The code encompasses both prescription pharmaceutical ingredients and finished goods acquired by health departments, correctional facilities, municipal hospitals, and other public entities through state cooperative vehicles and direct municipal RFPs. Issuing bodies soliciting under this code include state procurement offices administering multi-state cooperative purchasing alliances, city and county health departments, and municipal water and facility management agencies. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered through the Minnesota Department of Administration's Office of State Procurement, represents the dominant recent issuing body, establishing master agreements for generic pharmaceuticals and OTC products distributed across participating state and local facilities in multiple states including Oregon.

Recent activity concentrates in the Upper Midwest and reflects two distinct procurement streams. MMCAP issued an RFP (S1070000015802) on January 20, 2026, with responses due March 26, 2026, seeking manufacturers of generic multi-source pharmaceuticals and OTC products for supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with contract effectiveness set for July 1, 2026. Concurrently, the City of Meriden, Connecticut posted an IFB (B02715) on July 8, 2026, with bids due July 29, 2026, for sodium bisulfite chemical supply supporting water treatment operations at its Water Pollution Control Facility. The MMCAP opportunity weights price competitiveness at 75 percent and requires vendors to maintain cGMP certification and Drug Supply Chain Security Act compliance, with a 3 percent administrative fee on all purchases. Performance bonds and liability insurance are required across all recent solicitations, with MMCAP specifying commercial general liability of $5,000,000 per occurrence.